Elevai Labs (ELAB) Stock Price, News & Analysis

Company Overview

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

Key Stats

• Today's Range: $0.02 to $0.03
• 50-Day Range: $0.02 to $0.35
• 52-Week Range: $0.02 to $4.24
• Volume: 380.03 million shs
• Average Volume: 30.43 million shs
• Market Capitalization: $459,901.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Elevai Labs Stock Analysis - MarketRank™

Elevai Labs scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Elevai Labs.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Elevai Labs is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elevai Labs is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Elevai Labs has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

56.82% of the float of Elevai Labs has been sold short.

Short Interest Ratio / Days to Cover

Elevai Labs has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elevai Labs has recently increased by 403.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elevai Labs does not currently pay a dividend.

Dividend Growth

Elevai Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

56.82% of the float of Elevai Labs has been sold short.

Short Interest Ratio / Days to Cover

Elevai Labs has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elevai Labs has recently increased by 403.74%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.18

News Sentiment

Elevai Labs has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Elevai Labs this week, compared to 1 article on an average week.

Search Interest

17 people have searched for ELAB on MarketBeat in the last 30 days. This is an increase of 467% compared to the previous 30 days.

MarketBeat Follows

4 people have added Elevai Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elevai Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

37.00% of the stock of Elevai Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 22.22% of the stock of Elevai Labs is held by institutions.

ELAB Stock Analysis - Frequently Asked Questions

How have ELAB shares performed this year?

Elevai Labs' stock was trading at $1.8282 at the beginning of 2024. Since then, ELAB shares have decreased by 98.8% and is now trading at $0.0221.
View the best growth stocks for 2024 here.

When did Elevai Labs IPO?

Elevai Labs (ELAB) raised $6 million in an initial public offering on Tuesday, November 21st 2023. The company issued 1,500,000 shares at a price of $4.00 per share. Univest Securities acted as the underwriter for the IPO.

How do I buy shares of Elevai Labs?

Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Elevai Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevai Labs investors own include BIOLASE (BIOL), Conduit Pharmaceuticals (CDT), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), TRACON Pharmaceuticals (TCON), Tempest Therapeutics (TPST) and 22nd Century Group (XXII).

Company Calendar

• Today: 11/18/2024
• Next Earnings (Estimated): 12/09/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELAB
• Previous Symbol: NASDAQ:ELAB
• CUSIP: N/A
• CIK: 1840563
• Web: elevaiskincare.com
• Phone: 866-794-4940
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,300,000.00
• Net Margins: -223.41%
• Pretax Margin: -191.92%
• Return on Equity: -183.22%
• Return on Assets: -113.15%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 1.05
• Quick Ratio: 0.54

Sales & Book Value

• Annual Sales: $1.71 million
• Price / Sales: 0.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 20,810,000
• Free Float: 13,107,000
• Market Cap: $459,901.00
• Optionable: N/A
• Beta: N/A